Hisano C, Nakano S, Okuma K, Masumoto N, Fujishima H, Nakamura M, Niho Y
First Dept. of Internal Medicine, Faculty of Medicine, Kyushu University, Japan.
Gan To Kagaku Ryoho. 1996 Aug;23(9):1175-81.
A crossover clinical trial between granisetron alone and granisetron combined with methylprednisolone (MPL) was undertaken for the prevention of nausea and vomiting during chemotherapy, including cisplatin, in 12 patients with advanced primary and metastatic lung cancer. The antiemetic effect was obtained in 91.7% (11/12 cases) of patients receiving granisetron alone compared to 100% (12/12 cases) of patients receiving the combination of granisetron plus MPL. Complete control of anorexia was achieved in 91.6% (11/12 cases) of patients receiving the combination compared to 58.3% (7/12 cases) of patients receiving granisetron alone. Moreover there was a significant improvement of delayed clinical symptoms including nausea, vomiting, and anorexia in the patients receiving the combination of granisetron plus MPL. Our data suggest that the antiemetic effect of the combination of granisetron plus MPL is superior to granisetron alone in patients receiving cancer chemotherapy.
对12例晚期原发性和转移性肺癌患者进行了一项交叉临床试验，比较单独使用格拉司琼与格拉司琼联合甲泼尼龙（MPL）预防包括顺铂在内的化疗期间恶心和呕吐的效果。单独接受格拉司琼治疗的患者中91.7%（11/12例）获得了止吐效果，而接受格拉司琼加MPL联合治疗的患者中这一比例为100%（12/12例）。接受联合治疗的患者中91.6%（11/12例）实现了对厌食症的完全控制，而单独接受格拉司琼治疗的患者中这一比例为58.3%（7/12例）。此外，接受格拉司琼加MPL联合治疗的患者在包括恶心、呕吐和厌食症在内的延迟临床症状方面有显著改善。我们的数据表明，在接受癌症化疗的患者中，格拉司琼加MPL联合治疗的止吐效果优于单独使用格拉司琼。
